Articles By Jack Cush, MD
RA Patients on Biologics and tsDMARDs are still High Risk
A new Swedish ARTIS registry study of key safety outcomes in rheumatoid arthritis (RA) patients receiving either targeted synthetic or biological disease-modifying antirheumatic drugs (b/ts DMARDs, including Janus Kinase inhibitors (JAKi)), has been updated and affirms previously held risks.
Read Article
Best Treatments for Immune Checkpoint Inhibitor-associated Arthritis
A retrospective study of cancer patients who developed immune checkpoint inhibitor-associated inflammatory arthritis (ICI-IA) shows that biologic DMARDs were more effective than conventional synthetic DMARDs (csDMARDs) in rapid control of arthritis.
Read Article
Clinical Profile of RA-associated Interstitial Lung Disease
A prospective, cross-sectional analysis of patients with rheumatoid arthritis (RA) shows those with interstitial lung disease (ILD) tend to be older, obese and have a smoking history.
Read Article
Rheumatologist - Work-Life Survey Results
During the week of April 3, 2023, registered Rheumatologists responded to an email survey regarding work-life balance. The following are the results from 190 respondents - 53% were male (47% female) and 94% were from the USA.
Read Article
“You Can Have it All” (4.7.2023)
Dr. Jack Cush reviews the news and highlights from our "Women in Rheumatology" Campaign from last week on RheumNow.com
Read Article
Antiphospholipid Antibodies With Incident Cardiovascular Events
Are antiphospholipid antibodies (aPL) associated with atherosclerotic cardiovascular (ASCVD) event risk? A cohort study has shown that aPL Abs are found in a substantial proportion of adults with ASCVD events and finding both positive aCL IgA and aβ2GPI IgA Abs independently predicted futur
Read Article
Disordered Pain Processing in Fibromyalgia
Fibromyalgia is a mysterious chronic pain disorder that is difficult to treat. Its causes are also still largely in the dark.
Read Article
Steroid-Sparing Rituximab in Polymyalgia Rheumatica
BRIDGE-PMR proof-of-concept trial assessed the efficacy of rituximab (RTX) in patients with polymyalgia rheumatica (PMR) and showed that a single 1000 mg dose of lead to a significant number of glucocorticoid-free remissions after 1 year.
Read Article
British Society of Rheumatology Plans Revision of Systemic Sclerosis Guideline
British Society for Rheumatology (BSR) last published its guideline for systemic sclerosis (SSc) in 2016. Given the many advances in the field the BSR has outlined their plans to update the management of SSc.
Read Article
EMA Final Update on JAK Inhibitors and MACE, Malignancy & VTE Risks
The EMA has updated recommendations regarding the use of JAK inhibitors by issuing a direct healthcare professional communication summarizing the data and warnings regarding an increased risk of malignancy, major adverse cardiovascular events (MACE), serious infections, VTE, and mortality in some patients receiving JAKi for the treatment of chronic inflammatory disorders.
Read Article
